{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:40:18Z","timestamp":1762980018655},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00277-013-1914-y","type":"journal-article","created":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T06:39:26Z","timestamp":1380523166000},"page":"43-46","source":"Crossref","is-referenced-by-count":14,"title":["Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia"],"prefix":"10.1007","volume":"93","author":[{"given":"David","family":"Mart\u00ednez-Cuadr\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Salamero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Vidriales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Bergua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Vives","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Carpio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca","family":"Rodr\u00edguez-Veiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Moscard\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,1]]},"reference":[{"key":"1914_CR1","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM). Acute Myeloid Leukemia. Version 2.2013. http:\/\/www.nccn.org\/index.asp . Accessed 16 April 2013"},{"issue":"14","key":"1914_CR2","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2009.26.4242","volume":"28","author":"AK Burnett","year":"2010","unstructured":"Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S et al (2010) European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 28(14):2389\u20132395","journal-title":"J Clin Oncol"},{"issue":"4","key":"1914_CR3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1200\/JCO.2009.23.3130","volume":"28","author":"HM Kantarjian","year":"2010","unstructured":"Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T et al (2010) Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28(4):549\u2013555","journal-title":"J Clin Oncol"},{"issue":"5","key":"1914_CR4","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/blood-2007-11-124602","volume":"112","author":"S Faderl","year":"2008","unstructured":"Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z et al (2008) A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112(5):1638\u20131645","journal-title":"Blood"},{"key":"1914_CR5","volume-title":"WHO Classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2008) WHO Classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon"},{"key":"1914_CR6","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH et al (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642\u20134649","journal-title":"J Clin Oncol"},{"key":"1914_CR7","unstructured":"Common terminology Criteria for Adverse Events (CTCAE). Version 4.0. http:\/\/ctep.cancer.gov\/reporting\/ctc.html . Accessed 16 April 2013"},{"issue":"18","key":"1914_CR8","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1002\/cncr.27429","volume":"118","author":"S Faderl","year":"2012","unstructured":"Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G et al (2012) Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471\u20134477","journal-title":"Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1914-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-013-1914-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1914-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:49:46Z","timestamp":1559036986000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-013-1914-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["1914"],"URL":"https:\/\/doi.org\/10.1007\/s00277-013-1914-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,1]]}}}